BioVie Inc. (BIVI)
Fuera de horario:
BioVie Inc.
680 West Nye Lane
Suite 204
Carson City, NV 89703
United States
775 888 3162
https://bioviepharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 18
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Cuong Viet Do M.B.A. | President, CEO & Director | 1.08M | N/D | 1966 |
| Ms. Joanne Wendy Kim CPA | CFO, Treasurer & Corporate Secretary | 397.38k | N/D | 1955 |
| Dr. Joseph M. Palumbo M.D. | Executive VP of R&D and Chief Medical Officer | 722k | N/D | 1960 |
| Mr. Clarence N. Ahlem | Senior Vice President of Operations | N/D | N/D | 1955 |
| Dr. Penelope Markham Ph.D. | Senior Vice President of Liver Disease Program | N/D | N/D | 1966 |
| Ms. Denise Smith | Senior Vice President of Manufacturing & Development | N/D | N/D | N/D |
| Dr. Christopher L. Reading Ph.D. | Senior Vice President of Alzheimer's Disease Program | N/D | N/D | 1948 |
| Ms. Sarah Overton Hoit | Chief Social Impact Officer | N/D | N/D | 1968 |
Descripción
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Gestión corporativa
La calificación ISS Governance QuickScore de BioVie Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 7; Derechos del accionista: 5; Compensación: 10.
